10-Q: MiNK Therapeutics Reports Q1 2025 Financial Results, Cites Going Concern Uncertainty Amidst Pipeline Development

MiNK Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to liquidity challenges, despite ongoing clinical development and pipeline advancements.

Summary

• MiNK Therapeutics reported a net loss of $2.77 million for the three months ended March 31, 2025, compared to a net loss of $3.81 million for the same period in 2024.
• Research and development expenses decreased by 51% to $1.3 million, primarily due to decreased costs associated with clinical trials and pre-clinical activities.
• General and administrative expenses remained relatively stable at $1.3 million.
• As of March 31, 2025, the company's cash and cash equivalents were $3.2 million.
• The company believes its current cash balance, plus anticipated funding, will be sufficient to meet liquidity requirements for more than one year; however, there is substantial doubt about its ability to continue as a going concern.
• MiNK is exploring strategic partnerships, non-dilutive financing, and equity or debt financing options to support its liquidity.
• The company's most advanced product candidate, agenT-797, is in Phase 2 clinical trials for gastric cancer and viral ARDS.
• IND-enabling activities are underway for MiNK-215 and MiNK-413, with an IND submission to the FDA expected in 2025.
• MiNK received a notice from Nasdaq on May 13, 2025, regarding non-compliance with the Minimum Value of Listed Securities (MVLS) rule and has until November 10, 2025, to regain compliance.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the going concern warning and Nasdaq compliance issue, despite some progress in clinical development and cost reduction efforts. The company's financial position raises significant concerns.

Positives

• The net loss decreased from $3.81 million in Q1 2024 to $2.77 million in Q1 2025.
• Research and development expenses decreased by 51%, indicating potential cost management.
• The company is actively pursuing strategic partnerships and financing options to improve its financial position.
• Clinical development of agenT-797 is advancing in multiple therapeutic areas.
• IND-enabling activities are underway for MiNK-215 and MiNK-413, with an IND submission to the FDA expected in 2025.

Negatives

• The company reported a net loss of $2.77 million for Q1 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's cash and cash equivalents were $3.2 million as of March 31, 2025, which may be insufficient to fund operations without additional financing.
• MiNK received a Nasdaq notice regarding MVLS non-compliance, which could lead to delisting if not addressed.

Risks

• The company's ability to continue as a going concern is uncertain due to liquidity challenges.
• Failure to secure additional funding through strategic partnerships, non-dilutive financing, or equity/debt offerings could negatively impact operations.
• Clinical trial delays or failures could impact the development and commercialization of product candidates.
• Regulatory approvals for new therapeutic products are lengthy, expensive, and uncertain.
• The company's reliance on Agenus for certain services and financing poses a risk.
• Failure to regain compliance with Nasdaq's MVLS rule could result in delisting of the company's stock.

Future Outlook

MiNK Therapeutics plans to advance its clinical programs, including agenT-797 in viral ARDS, through strategic collaborations and non-dilutive external financing. The company also expects to submit an IND to the FDA in 2025 for its engineered iNKT programs, MiNK-215 and MiNK-413. The company will require additional funding to support its liquidity requirements and is exploring various financing options.

Management Comments

• Management continually monitors the Company's liquidity position and adjusts spending as needed in order to preserve liquidity.
• Management believes that its cash and cash equivalents balance, plus anticipated funding, will be sufficient to satisfy its liquidity requirements for more than one year from when these financial statements were issued.

Industry Context

MiNK Therapeutics is operating in the competitive biopharmaceutical industry, specifically focusing on allogeneic, off-the-shelf, iNKT cell therapies. The company's focus on cancer and immune-mediated diseases aligns with significant unmet needs in these therapeutic areas. The collaboration with ImmunoScape to discover and develop next-generation T-cell receptor therapies against novel targets in solid tumors is a common strategy in the industry to enhance pipeline development and leverage external expertise.

Comparison to Industry Standards

• Comparing MiNK Therapeutics to companies like Allogene Therapeutics, Atara Biotherapeutics, and Nkarta Therapeutics, which are also focused on allogeneic cell therapies, MiNK's cash position of $3.2 million is significantly lower.
• Allogene Therapeutics, for example, reported cash and investments of $261.3 million as of March 31, 2024.
• Atara Biotherapeutics reported $179.3 million in cash, cash equivalents, and investments as of March 31, 2024.
• Nkarta Therapeutics reported $224.1 million in cash, cash equivalents, and investments as of March 31, 2024.
• This comparison highlights MiNK's urgent need for additional funding to sustain its operations and clinical development programs.
• MiNK's reliance on related-party funding from Agenus is also a differentiating factor compared to these other companies, which have typically raised capital through public offerings or venture financing.

Legal Proceedings

• In 2022, the Company received notice that the Walloon Region had obtained a default judgment seeking repayment of approximately $ 2.3 million of the advance based upon the Company allegedly not providing required notification that research and operations in the region were discontinued.

Related Party Transactions

• MiNK relies on Agenus for certain services and financing.
• Agenus has agreed to not require repayment of the balance due for the foreseeable future.
• The company's CEO is also an employee and board member of Agenus.
• Dr. Buell's spouse is a partner in the law firm of Wolf, Greenfield & Sachs, P.C. (Wolf Greenfield), which provided legal services to the Company during the periods ended March 31, 2025 and 2024, and continues to do so.

Stakeholder Impact

• Shareholders face the risk of stock delisting if the company fails to regain compliance with Nasdaq's MVLS rule.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers and partners may be affected by potential delays or disruptions in the development and commercialization of product candidates.
• Creditors face increased risk of non-payment if the company's liquidity challenges persist.

Next Steps

• MiNK will continue to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule.
• MiNK will seek strategic partnerships and collaborations, as well as out-licensing opportunities, for its portfolio programs and product candidates.
• MiNK will explore avenues for securing non-dilutive financing, such as grants, collaborations, and providing fee-based services to strengthen its balance sheet.
• MiNK will consider potential equity or debt financing options.
• MiNK expects to submit an IND to the FDA in 2025 for its engineered iNKT programs, MiNK-215 and MiNK-413.

Key Dates

Keywords

iNKT cell therapy, agenT-797, MiNK-215, MiNK-413, clinical trials, biopharmaceutical, financial results, liquidity, going concern, Nasdaq, MVLS, Agenus, research and development